longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Cafรฉ
longbridge
ยฉ 2026 Longbridge๏ฝœTerms of ServicePrivacy Policy

TEMT

TEMT
21.3501.18%( +0.250 )

LongbridgeAI
H
Hardik Shah

May 29 at 12:27 PM

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $Tempus AI(TEM.US) FDA Approves Tempus AIโ€™s xT CDx for Tumor-Only Genomic Profiling

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค FDA grants ๐ญ๐ฎ๐ฆ๐จ๐ซ-๐จ๐ง๐ฅ๐ฒ approval for Tempus AIโ€™s ๐ฑ๐“ ๐‚๐ƒ๐ฑ platform.

โžค Tempus becomes first lab with FDA-approved ๐ญ๐ฎ๐ฆ๐จ๐ซ-๐จ๐ง๐ฅ๐ฒ and ๐ญ๐ฎ๐ฆ๐จ๐ซ-๐ง๐จ๐ซ๐ฆ๐š๐ฅ CDx profiling.

โžค xT CDx is a ๐Ÿ”๐Ÿ’๐Ÿ–-๐ ๐ž๐ง๐ž assay for comprehensive solid tumor profiling.

โžค Approval allows testing when matched blood or saliva samples are unavailable.

โžค Platform serves as a ๐œ๐จ๐ฆ๐ฉ๐š๐ง๐ข๐จ๐ง ๐๐ข๐š๐ ๐ง๐จ๐ฌ๐ญ๐ข๐œ for certain colorectal cancer therapies.

โžค Tempus plans to migrate its DNA tumor portfolio to ๐…๐ƒ๐€-๐š๐ฉ๐ฉ๐ซ๐จ๐ฏ๐ž๐ assays.

โžค Company expects an estimated $๐Ÿ๐ŸŽ๐ŸŽ ๐€๐’๐ benefit beginning in ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ•

Tempus AI

Tempus AI

USTEM

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.